<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601731</url>
  </required_header>
  <id_info>
    <org_study_id>V59P5E1</org_study_id>
    <secondary_id>2007-004978-16</secondary_id>
    <nct_id>NCT00601731</nct_id>
  </id_info>
  <brief_title>Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months</brief_title>
  <official_title>A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months Who Have Previously Received Novartis MenACWY Conjugate Vaccine as Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how well the immuno response against meningococcal
      serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:8</measure>
    <time_frame>At 40 and 60 months of age</time_frame>
    <description>Percentages of subjects with human Serum Bactericidal Assay (hSBA) ≥1:8 as measured by serum bactericidal activity at 40 months and 60 months of age and associated 95% Clopper-Pearson CIs were computed for each of the serogroups within each of the vaccinated groups and in age-matched control subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:4</measure>
    <time_frame>At 40 and 60 months of age</time_frame>
    <description>Percentages of subjects with hSBA ≥1:4 as measured by serum bactericidal activity at 40 months and 60 months of age and associated 95% Clopper-Pearson CIs were computed for each of the serogroups within each of the vaccinated groups and in age-matched control subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs in Subjects Within Each Site and in Age-Matched Control Subjects</measure>
    <time_frame>At 40 and 60 months of age</time_frame>
    <description>The Geometric Mean Titers (GMTs) as measured by serum bactericidal activity at 40 months and 60 months of age and 95% CIs were calculated for each vaccine group and for each serogroup by exponentiating (base 10) the least square means of the logarithmically transformed (base 10) titers and their 95% CIs obtained from a two-way Analysis of Variance (ANOVA) with factors for vaccine group and center.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">382</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Adjuvanted MenACWY vaccine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-adjuvanted MenACWY vaccine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood test</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM197</intervention_name>
    <description>Blood test, 40-months and 60-months children</description>
    <arm_group_label>Adjuvanted MenACWY vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood test, 40-months and 60-months children</description>
    <arm_group_label>Non-adjuvanted MenACWY vaccine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Follow-on, healthy 40, 60 months old participants who have completed the V59P5 study
             and are in good health

          -  Control subjects: healthy 60 months old who had received a complete MenC immunization
             course

        Exclusion Criteria:

          -  Subjects with any serious, acute or chronic progressive disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Months</minimum_age>
    <maximum_age>63 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials Research Center</name>
      <address>
        <city>Halifax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaccine Evaluation Center</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Vaccine Group</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>October 28, 2011</results_first_submitted>
  <results_first_submitted_qc>September 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2012</results_first_posted>
  <disposition_first_submitted>July 20, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 20, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 25, 2011</disposition_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of Meningococcal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 3 sites (1 site in the UK and 2 sites in Canada).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>UK Site</title>
          <description>UK vaccine group that received primary vaccine schedule of MenACWY (adjuvanted and unadjuvanted) vaccine at 2, 3 and 4 months with booster at 12 months of age, enrolled at either 40 or 60 months of age into the current study as follow-on participants.</description>
        </group>
        <group group_id="P2">
          <title>UK Control</title>
          <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2, 3 and 4 months of age without any booster vaccination.</description>
        </group>
        <group group_id="P3">
          <title>Canada Sites</title>
          <description>Canadian vaccine group that received primary vaccination with MenACWY (adjuvanted and unadjuvanted) vaccine at 2,4 months of age with 12 month booster or at 2, 4, 6 months with or without a booster vaccination.</description>
        </group>
        <group group_id="P4">
          <title>Canada Control</title>
          <description>Newly enrolled age-matched subjects that received the complete vaccination course of routine monovalent MenC conjugate vaccine at 2 and 12 months or only at 12 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="166"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>UK2,3,4,12+</title>
          <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 3, and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
        </group>
        <group group_id="B2">
          <title>UK2,4,12+</title>
          <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
        </group>
        <group group_id="B3">
          <title>UK2,4C/12+</title>
          <description>UK vaccine group receiving primary vaccine of monovalent MenC-CRM197 conjugate vaccine (Menjugate) at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
        </group>
        <group group_id="B4">
          <title>UK2,4,12-</title>
          <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
        </group>
        <group group_id="B5">
          <title>UK Control</title>
          <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2, 3 and 4 months of age without any booster vaccination.</description>
        </group>
        <group group_id="B6">
          <title>Ca2,4,6+</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age without any booster vaccination.</description>
        </group>
        <group group_id="B7">
          <title>Ca2,4,6+/12PS</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age</description>
        </group>
        <group group_id="B8">
          <title>Ca2,4,12+</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
        </group>
        <group group_id="B9">
          <title>Ca2,4+/12PS</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
        </group>
        <group group_id="B10">
          <title>Ca2,4,12-</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster vaccination of the quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
        </group>
        <group group_id="B11">
          <title>Ca2,4-/12PS</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of the quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
        </group>
        <group group_id="B12">
          <title>Ca Control</title>
          <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2 and 12 months or only at 12 months of age.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="37"/>
            <count group_id="B5" value="43"/>
            <count group_id="B6" value="31"/>
            <count group_id="B7" value="26"/>
            <count group_id="B8" value="27"/>
            <count group_id="B9" value="28"/>
            <count group_id="B10" value="27"/>
            <count group_id="B11" value="27"/>
            <count group_id="B12" value="30"/>
            <count group_id="B13" value="382"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>40 months (N=36,37,19,34,0,28,23,27,28,25,26,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="0.7"/>
                    <measurement group_id="B2" value="42.6" spread="0.6"/>
                    <measurement group_id="B3" value="42.6" spread="0.5"/>
                    <measurement group_id="B4" value="40.6" spread="0.8"/>
                    <measurement group_id="B5" value="NA">Zero participants were in this subgroup.</measurement>
                    <measurement group_id="B6" value="42" spread="1"/>
                    <measurement group_id="B7" value="41.8" spread="1.2"/>
                    <measurement group_id="B8" value="42" spread="0.9"/>
                    <measurement group_id="B9" value="41.6" spread="1"/>
                    <measurement group_id="B10" value="40.7" spread="1"/>
                    <measurement group_id="B11" value="41.0" spread="1.1"/>
                    <measurement group_id="B12" value="NA">Zero participants were in this subgroup.</measurement>
                    <measurement group_id="B13" value="34.78" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 months (N=4,7,3,3,43,3,3,0,0,2,1,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="1.0"/>
                    <measurement group_id="B2" value="61.3" spread="0.5"/>
                    <measurement group_id="B3" value="61.0" spread="1.0"/>
                    <measurement group_id="B4" value="61.7" spread="0.6"/>
                    <measurement group_id="B5" value="61.9" spread="0.3"/>
                    <measurement group_id="B6" value="60.3" spread="0.6"/>
                    <measurement group_id="B7" value="61.3" spread="0.6"/>
                    <measurement group_id="B8" value="NA">Zero participants in this subgroup.</measurement>
                    <measurement group_id="B9" value="NA">Zero participants in this subgroup.</measurement>
                    <measurement group_id="B10" value="60.5" spread="0.7"/>
                    <measurement group_id="B11" value="60.0" spread="0.0"/>
                    <measurement group_id="B12" value="60.6" spread="0.6"/>
                    <measurement group_id="B13" value="60.88" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Number of subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female 40 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="NA">Zero participants were in this subgroup.</measurement>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="NA">Zero participants were in this subgroup.</measurement>
                    <measurement group_id="B13" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male 40 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="NA">Zero participants were in this subgroup.</measurement>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="13"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="NA">Zero participants were in this subgroup.</measurement>
                    <measurement group_id="B13" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female 60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="NA">Zero participants in this subgroup.</measurement>
                    <measurement group_id="B9" value="NA">Zero participants in this subgroup.</measurement>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="15"/>
                    <measurement group_id="B13" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male 60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="NA">Zero participants in this subgroup.</measurement>
                    <measurement group_id="B9" value="NA">Zero participants in this subgroup.</measurement>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="15"/>
                    <measurement group_id="B13" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With hSBA ≥1:8</title>
        <description>Percentages of subjects with human Serum Bactericidal Assay (hSBA) ≥1:8 as measured by serum bactericidal activity at 40 months and 60 months of age and associated 95% Clopper-Pearson CIs were computed for each of the serogroups within each of the vaccinated groups and in age-matched control subjects.</description>
        <time_frame>At 40 and 60 months of age</time_frame>
        <population>Immunogenicity was evaluated in the Modified Intent To Treat (MITT) population that included subjects who provided at least one evaluable blood sample. Thus, the difference in the number of subjects entered here versus the number of subjects in the participant flow and baseline characteristics (i.e., enrolled subjects) module.</population>
        <group_list>
          <group group_id="O1">
            <title>UK2,3,4,12+</title>
            <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 3, and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK2,4,12+</title>
            <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK2,4C/12+</title>
            <description>UK vaccine group receiving primary vaccine of monovalent MenC-CRM197 conjugate vaccine (Menjugate) at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>UK2,4,12-</title>
            <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>UK Control</title>
            <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2, 3 and 4 months of age without any booster vaccination.</description>
          </group>
          <group group_id="O6">
            <title>Ca2,4,6+</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age without any booster vaccination.</description>
          </group>
          <group group_id="O7">
            <title>Ca2,4,6+/12PS</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age</description>
          </group>
          <group group_id="O8">
            <title>Ca2,4,12+</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O9">
            <title>Ca2,4+/12PS</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
          </group>
          <group group_id="O10">
            <title>Ca2,4,12-</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster vaccination of the quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O11">
            <title>Ca2,4-/12PS</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of the quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
          </group>
          <group group_id="O12">
            <title>Ca Control</title>
            <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2 and 12 months or only at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:8</title>
          <description>Percentages of subjects with human Serum Bactericidal Assay (hSBA) ≥1:8 as measured by serum bactericidal activity at 40 months and 60 months of age and associated 95% Clopper-Pearson CIs were computed for each of the serogroups within each of the vaccinated groups and in age-matched control subjects.</description>
          <population>Immunogenicity was evaluated in the Modified Intent To Treat (MITT) population that included subjects who provided at least one evaluable blood sample. Thus, the difference in the number of subjects entered here versus the number of subjects in the participant flow and baseline characteristics (i.e., enrolled subjects) module.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="25"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA 40mths N=33,37,17,34,0,28,23,27,28,25,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="13" upper_limit="46"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="22"/>
                    <measurement group_id="O3" value="29" lower_limit="10" upper_limit="56"/>
                    <measurement group_id="O4" value="3" lower_limit="0.074" upper_limit="15"/>
                    <measurement group_id="O5" value="NA">zero participants analyzed</measurement>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O7" value="4" lower_limit="0" upper_limit="22"/>
                    <measurement group_id="O8" value="7" lower_limit="1" upper_limit="24"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O10" value="8" lower_limit="1" upper_limit="26"/>
                    <measurement group_id="O11" value="0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O12" value="NA">zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenA 60mths N=33,35,18,31,42,27,25,23,25,23,24,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="2" upper_limit="24"/>
                    <measurement group_id="O2" value="11" lower_limit="3" upper_limit="27"/>
                    <measurement group_id="O3" value="11" lower_limit="1" upper_limit="35"/>
                    <measurement group_id="O4" value="3" lower_limit="0.082" upper_limit="17"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="13"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O8" value="4" lower_limit="0" upper_limit="22"/>
                    <measurement group_id="O9" value="4" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O10" value="4" lower_limit="0" upper_limit="22"/>
                    <measurement group_id="O11" value="0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O12" value="3" lower_limit="0.084" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC 40mths N=32,36,17,33,0,20,22,26,26,24,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="24" upper_limit="59"/>
                    <measurement group_id="O2" value="47" lower_limit="30" upper_limit="65"/>
                    <measurement group_id="O3" value="71" lower_limit="44" upper_limit="90"/>
                    <measurement group_id="O4" value="33" lower_limit="18" upper_limit="52"/>
                    <measurement group_id="O5" value="NA">zero participants analyzed</measurement>
                    <measurement group_id="O6" value="20" lower_limit="6" upper_limit="44"/>
                    <measurement group_id="O7" value="14" lower_limit="3" upper_limit="35"/>
                    <measurement group_id="O8" value="31" lower_limit="14" upper_limit="52"/>
                    <measurement group_id="O9" value="35" lower_limit="17" upper_limit="56"/>
                    <measurement group_id="O10" value="38" lower_limit="19" upper_limit="59"/>
                    <measurement group_id="O11" value="46" lower_limit="26" upper_limit="67"/>
                    <measurement group_id="O12" value="NA">zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC 60mths N=32,34,17,31,42,21,24,22,21,22,24,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="19" upper_limit="53"/>
                    <measurement group_id="O2" value="32" lower_limit="17" upper_limit="51"/>
                    <measurement group_id="O3" value="59" lower_limit="33" upper_limit="82"/>
                    <measurement group_id="O4" value="45" lower_limit="27" upper_limit="64"/>
                    <measurement group_id="O5" value="29" lower_limit="16" upper_limit="45"/>
                    <measurement group_id="O6" value="14" lower_limit="3" upper_limit="36"/>
                    <measurement group_id="O7" value="13" lower_limit="3" upper_limit="32"/>
                    <measurement group_id="O8" value="14" lower_limit="3" upper_limit="35"/>
                    <measurement group_id="O9" value="24" lower_limit="8" upper_limit="47"/>
                    <measurement group_id="O10" value="27" lower_limit="11" upper_limit="50"/>
                    <measurement group_id="O11" value="46" lower_limit="26" upper_limit="67"/>
                    <measurement group_id="O12" value="53" lower_limit="34" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW 40mths N=33,36,17,34,0,28,23,27,28,25,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="54" upper_limit="87"/>
                    <measurement group_id="O2" value="69" lower_limit="52" upper_limit="84"/>
                    <measurement group_id="O3" value="71" lower_limit="44" upper_limit="90"/>
                    <measurement group_id="O4" value="74" lower_limit="56" upper_limit="87"/>
                    <measurement group_id="O5" value="NA">zero participants analyzed</measurement>
                    <measurement group_id="O6" value="29" lower_limit="13" upper_limit="49"/>
                    <measurement group_id="O7" value="48" lower_limit="27" upper_limit="69"/>
                    <measurement group_id="O8" value="59" lower_limit="39" upper_limit="78"/>
                    <measurement group_id="O9" value="43" lower_limit="24" upper_limit="63"/>
                    <measurement group_id="O10" value="72" lower_limit="51" upper_limit="88"/>
                    <measurement group_id="O11" value="58" lower_limit="37" upper_limit="78"/>
                    <measurement group_id="O12" value="NA">zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW 60mths N=32,34,18,31,42,26,25,23,24,21,24,29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="50" upper_limit="84"/>
                    <measurement group_id="O2" value="85" lower_limit="69" upper_limit="95"/>
                    <measurement group_id="O3" value="78" lower_limit="52" upper_limit="94"/>
                    <measurement group_id="O4" value="84" lower_limit="66" upper_limit="95"/>
                    <measurement group_id="O5" value="36" lower_limit="22" upper_limit="52"/>
                    <measurement group_id="O6" value="31" lower_limit="14" upper_limit="52"/>
                    <measurement group_id="O7" value="44" lower_limit="24" upper_limit="65"/>
                    <measurement group_id="O8" value="57" lower_limit="34" upper_limit="77"/>
                    <measurement group_id="O9" value="42" lower_limit="22" upper_limit="63"/>
                    <measurement group_id="O10" value="81" lower_limit="58" upper_limit="95"/>
                    <measurement group_id="O11" value="67" lower_limit="45" upper_limit="84"/>
                    <measurement group_id="O12" value="34" lower_limit="18" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY 40mths N=33,36,17,34,0,28,23,27,28,25,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="58" upper_limit="89"/>
                    <measurement group_id="O2" value="61" lower_limit="43" upper_limit="77"/>
                    <measurement group_id="O3" value="76" lower_limit="50" upper_limit="93"/>
                    <measurement group_id="O4" value="53" lower_limit="35" upper_limit="70"/>
                    <measurement group_id="O5" value="NA">zero participants analyzed</measurement>
                    <measurement group_id="O6" value="32" lower_limit="16" upper_limit="52"/>
                    <measurement group_id="O7" value="26" lower_limit="10" upper_limit="48"/>
                    <measurement group_id="O8" value="44" lower_limit="25" upper_limit="65"/>
                    <measurement group_id="O9" value="21" lower_limit="8" upper_limit="41"/>
                    <measurement group_id="O10" value="64" lower_limit="43" upper_limit="82"/>
                    <measurement group_id="O11" value="63" lower_limit="41" upper_limit="81"/>
                    <measurement group_id="O12" value="NA">zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY 60mths N=33,34,17,31,42,27,25,23,23,21,23,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="42" upper_limit="77"/>
                    <measurement group_id="O2" value="71" lower_limit="53" upper_limit="85"/>
                    <measurement group_id="O3" value="71" lower_limit="44" upper_limit="90"/>
                    <measurement group_id="O4" value="42" lower_limit="25" upper_limit="61"/>
                    <measurement group_id="O5" value="29" lower_limit="16" upper_limit="45"/>
                    <measurement group_id="O6" value="30" lower_limit="14" upper_limit="50"/>
                    <measurement group_id="O7" value="24" lower_limit="9" upper_limit="45"/>
                    <measurement group_id="O8" value="43" lower_limit="23" upper_limit="66"/>
                    <measurement group_id="O9" value="22" lower_limit="7" upper_limit="44"/>
                    <measurement group_id="O10" value="57" lower_limit="34" upper_limit="78"/>
                    <measurement group_id="O11" value="57" lower_limit="34" upper_limit="77"/>
                    <measurement group_id="O12" value="10" lower_limit="2" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:4</title>
        <description>Percentages of subjects with hSBA ≥1:4 as measured by serum bactericidal activity at 40 months and 60 months of age and associated 95% Clopper-Pearson CIs were computed for each of the serogroups within each of the vaccinated groups and in age-matched control subjects.</description>
        <time_frame>At 40 and 60 months of age</time_frame>
        <population>The analysis was done on MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>UK2,3,4,12+</title>
            <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 3, and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK2,4,12+</title>
            <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK2,4C/12+</title>
            <description>UK vaccine group receiving primary vaccine of monovalent MenC-CRM197 conjugate vaccine (Menjugate) at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>UK2,4,12-</title>
            <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>UK Control</title>
            <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2, 3 and 4 months of age without any booster vaccination.</description>
          </group>
          <group group_id="O6">
            <title>Ca2,4,6+</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age without any booster vaccination.</description>
          </group>
          <group group_id="O7">
            <title>Ca2,4,6+/12PS</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age</description>
          </group>
          <group group_id="O8">
            <title>Ca2,4,12+</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O9">
            <title>Ca2,4+/12PS</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
          </group>
          <group group_id="O10">
            <title>Ca2,4,12-</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster vaccination of the quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O11">
            <title>Ca2,4-/12PS</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of the quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
          </group>
          <group group_id="O12">
            <title>Ca Control</title>
            <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2 and 12 months or only at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:4</title>
          <description>Percentages of subjects with hSBA ≥1:4 as measured by serum bactericidal activity at 40 months and 60 months of age and associated 95% Clopper-Pearson CIs were computed for each of the serogroups within each of the vaccinated groups and in age-matched control subjects.</description>
          <population>The analysis was done on MITT population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="25"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA 40mths N=33,37,17,34,0,28,23,27,28,25,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="16" upper_limit="49"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="22"/>
                    <measurement group_id="O3" value="29" lower_limit="10" upper_limit="56"/>
                    <measurement group_id="O4" value="3" lower_limit="0.074" upper_limit="15"/>
                    <measurement group_id="O5" value="NA">Zero participants analyzed</measurement>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O7" value="4" lower_limit="0" upper_limit="22"/>
                    <measurement group_id="O8" value="11" lower_limit="2" upper_limit="29"/>
                    <measurement group_id="O9" value="7" lower_limit="1" upper_limit="24"/>
                    <measurement group_id="O10" value="8" lower_limit="1" upper_limit="26"/>
                    <measurement group_id="O11" value="0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O12" value="NA">Zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenA 60mths N=33,35,18,31,42,27,25,23,25,23,24,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="5" upper_limit="32"/>
                    <measurement group_id="O2" value="11" lower_limit="3" upper_limit="27"/>
                    <measurement group_id="O3" value="22" lower_limit="6" upper_limit="48"/>
                    <measurement group_id="O4" value="3" lower_limit="0.082" upper_limit="17"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O6" value="4" lower_limit="0.094" upper_limit="19"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O8" value="9" lower_limit="1" upper_limit="28"/>
                    <measurement group_id="O9" value="4" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O10" value="9" lower_limit="1" upper_limit="28"/>
                    <measurement group_id="O11" value="0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O12" value="7" lower_limit="1" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC 40mths N=32,36,17,33,0,20,22,26,26,24,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="29" upper_limit="65"/>
                    <measurement group_id="O2" value="53" lower_limit="35" upper_limit="70"/>
                    <measurement group_id="O3" value="71" lower_limit="44" upper_limit="90"/>
                    <measurement group_id="O4" value="42" lower_limit="25" upper_limit="61"/>
                    <measurement group_id="O5" value="NA">Zero participants analyzed</measurement>
                    <measurement group_id="O6" value="20" lower_limit="6" upper_limit="44"/>
                    <measurement group_id="O7" value="14" lower_limit="3" upper_limit="35"/>
                    <measurement group_id="O8" value="38" lower_limit="20" upper_limit="59"/>
                    <measurement group_id="O9" value="54" lower_limit="33" upper_limit="73"/>
                    <measurement group_id="O10" value="54" lower_limit="33" upper_limit="74"/>
                    <measurement group_id="O11" value="54" lower_limit="33" upper_limit="74"/>
                    <measurement group_id="O12" value="NA">Zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC 60mths N=32,34,17,31,42,21,24,22,21,22,24,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="32" upper_limit="68"/>
                    <measurement group_id="O2" value="44" lower_limit="27" upper_limit="62"/>
                    <measurement group_id="O3" value="71" lower_limit="44" upper_limit="90"/>
                    <measurement group_id="O4" value="52" lower_limit="33" upper_limit="70"/>
                    <measurement group_id="O5" value="40" lower_limit="26" upper_limit="57"/>
                    <measurement group_id="O6" value="24" lower_limit="8" upper_limit="47"/>
                    <measurement group_id="O7" value="29" lower_limit="13" upper_limit="51"/>
                    <measurement group_id="O8" value="32" lower_limit="14" upper_limit="55"/>
                    <measurement group_id="O9" value="48" lower_limit="26" upper_limit="70"/>
                    <measurement group_id="O10" value="59" lower_limit="36" upper_limit="79"/>
                    <measurement group_id="O11" value="58" lower_limit="37" upper_limit="78"/>
                    <measurement group_id="O12" value="67" lower_limit="47" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW 40mths N=33,36,17,34,0,28,23,27,28,25,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="54" upper_limit="87"/>
                    <measurement group_id="O2" value="69" lower_limit="52" upper_limit="84"/>
                    <measurement group_id="O3" value="71" lower_limit="44" upper_limit="90"/>
                    <measurement group_id="O4" value="85" lower_limit="69" upper_limit="95"/>
                    <measurement group_id="O5" value="NA">Zero participants analyzed</measurement>
                    <measurement group_id="O6" value="29" lower_limit="13" upper_limit="49"/>
                    <measurement group_id="O7" value="52" lower_limit="31" upper_limit="73"/>
                    <measurement group_id="O8" value="63" lower_limit="42" upper_limit="81"/>
                    <measurement group_id="O9" value="54" lower_limit="34" upper_limit="72"/>
                    <measurement group_id="O10" value="72" lower_limit="51" upper_limit="88"/>
                    <measurement group_id="O11" value="71" lower_limit="49" upper_limit="87"/>
                    <measurement group_id="O12" value="NA">Zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW 60mths N=32,34,18,31,42,26,25,23,24,21,24,29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="50" upper_limit="84"/>
                    <measurement group_id="O2" value="85" lower_limit="69" upper_limit="95"/>
                    <measurement group_id="O3" value="83" lower_limit="59" upper_limit="96"/>
                    <measurement group_id="O4" value="84" lower_limit="66" upper_limit="95"/>
                    <measurement group_id="O5" value="39" lower_limit="22" upper_limit="52"/>
                    <measurement group_id="O6" value="31" lower_limit="14" upper_limit="52"/>
                    <measurement group_id="O7" value="52" lower_limit="31" upper_limit="72"/>
                    <measurement group_id="O8" value="61" lower_limit="39" upper_limit="80"/>
                    <measurement group_id="O9" value="50" lower_limit="29" upper_limit="71"/>
                    <measurement group_id="O10" value="81" lower_limit="58" upper_limit="95"/>
                    <measurement group_id="O11" value="67" lower_limit="45" upper_limit="84"/>
                    <measurement group_id="O12" value="34" lower_limit="18" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY 40mths N=33,36,17,34,0,28,23,27,28,25,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="58" upper_limit="89"/>
                    <measurement group_id="O2" value="78" lower_limit="61" upper_limit="90"/>
                    <measurement group_id="O3" value="88" lower_limit="64" upper_limit="99"/>
                    <measurement group_id="O4" value="71" lower_limit="53" upper_limit="85"/>
                    <measurement group_id="O5" value="NA">Zero participants analyzed</measurement>
                    <measurement group_id="O6" value="50" lower_limit="31" upper_limit="69"/>
                    <measurement group_id="O7" value="35" lower_limit="16" upper_limit="57"/>
                    <measurement group_id="O8" value="59" lower_limit="39" upper_limit="78"/>
                    <measurement group_id="O9" value="43" lower_limit="24" upper_limit="63"/>
                    <measurement group_id="O10" value="68" lower_limit="46" upper_limit="85"/>
                    <measurement group_id="O11" value="63" lower_limit="41" upper_limit="81"/>
                    <measurement group_id="O12" value="NA">Zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY 60mths N=33,34,17,31,42,27,25,23,23,21,23,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="54" upper_limit="87"/>
                    <measurement group_id="O2" value="79" lower_limit="62" upper_limit="91"/>
                    <measurement group_id="O3" value="76" lower_limit="50" upper_limit="93"/>
                    <measurement group_id="O4" value="55" lower_limit="36" upper_limit="73"/>
                    <measurement group_id="O5" value="33" lower_limit="20" upper_limit="50"/>
                    <measurement group_id="O6" value="48" lower_limit="29" upper_limit="68"/>
                    <measurement group_id="O7" value="40" lower_limit="21" upper_limit="61"/>
                    <measurement group_id="O8" value="57" lower_limit="34" upper_limit="77"/>
                    <measurement group_id="O9" value="35" lower_limit="16" upper_limit="57"/>
                    <measurement group_id="O10" value="62" lower_limit="38" upper_limit="82"/>
                    <measurement group_id="O11" value="61" lower_limit="39" upper_limit="80"/>
                    <measurement group_id="O12" value="13" lower_limit="4" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs in Subjects Within Each Site and in Age-Matched Control Subjects</title>
        <description>The Geometric Mean Titers (GMTs) as measured by serum bactericidal activity at 40 months and 60 months of age and 95% CIs were calculated for each vaccine group and for each serogroup by exponentiating (base 10) the least square means of the logarithmically transformed (base 10) titers and their 95% CIs obtained from a two-way Analysis of Variance (ANOVA) with factors for vaccine group and center.</description>
        <time_frame>At 40 and 60 months of age</time_frame>
        <population>The analysis was done on MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>UK2,3,4,12+</title>
            <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 3, and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK2,4,12+</title>
            <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK2,4C/12+</title>
            <description>UK vaccine group receiving primary vaccine of monovalent MenC-CRM197 conjugate vaccine (Menjugate) at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>UK2,4,12-</title>
            <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>UK Control</title>
            <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2, 3 and 4 months of age without any booster vaccination.</description>
          </group>
          <group group_id="O6">
            <title>Ca2,4,6+</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age without any booster vaccination.</description>
          </group>
          <group group_id="O7">
            <title>Ca2,4,6+/12PS</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age</description>
          </group>
          <group group_id="O8">
            <title>Ca2,4,12+</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O9">
            <title>Ca2,4+/12PS</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
          </group>
          <group group_id="O10">
            <title>Ca2,4,12-</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster vaccination of the quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
          </group>
          <group group_id="O11">
            <title>Ca2,4-/12PS</title>
            <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of the quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
          </group>
          <group group_id="O12">
            <title>Ca Control</title>
            <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2 and 12 months or only at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs in Subjects Within Each Site and in Age-Matched Control Subjects</title>
          <description>The Geometric Mean Titers (GMTs) as measured by serum bactericidal activity at 40 months and 60 months of age and 95% CIs were calculated for each vaccine group and for each serogroup by exponentiating (base 10) the least square means of the logarithmically transformed (base 10) titers and their 95% CIs obtained from a two-way Analysis of Variance (ANOVA) with factors for vaccine group and center.</description>
          <population>The analysis was done on MITT population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="25"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA 40mths N=33,37,17,34,0,28,23,27,28,25,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" lower_limit="2.76" upper_limit="5.11"/>
                    <measurement group_id="O2" value="2.58" lower_limit="1.93" upper_limit="3.45"/>
                    <measurement group_id="O3" value="4.33" lower_limit="2.82" upper_limit="6.66"/>
                    <measurement group_id="O4" value="2.08" lower_limit="1.54" upper_limit="2.82"/>
                    <measurement group_id="O5" value="NA">Zero participants analyzed</measurement>
                    <measurement group_id="O6" value="2.01" lower_limit="1.69" upper_limit="2.39"/>
                    <measurement group_id="O7" value="2.17" lower_limit="1.79" upper_limit="2.39"/>
                    <measurement group_id="O8" value="2.56" lower_limit="2.15" upper_limit="3.05"/>
                    <measurement group_id="O9" value="2.11" lower_limit="1.77" upper_limit="2.5"/>
                    <measurement group_id="O10" value="2.41" lower_limit="2.01" upper_limit="2.89"/>
                    <measurement group_id="O11" value="2" lower_limit="1.66" upper_limit="2.4"/>
                    <measurement group_id="O12" value="NA">Zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenA 60mths N=33,35,18,31,42,27,25,23,25,23,24,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.12" upper_limit="3.19"/>
                    <measurement group_id="O2" value="2.69" lower_limit="2.21" upper_limit="3.28"/>
                    <measurement group_id="O3" value="2.85" lower_limit="2.16" upper_limit="3.75"/>
                    <measurement group_id="O4" value="2.11" lower_limit="1.71" upper_limit="2.61"/>
                    <measurement group_id="O5" value="2" lower_limit="1.67" upper_limit="2.39"/>
                    <measurement group_id="O6" value="2.08" lower_limit="1.77" upper_limit="2.45"/>
                    <measurement group_id="O7" value="2" lower_limit="1.69" upper_limit="2.36"/>
                    <measurement group_id="O8" value="2.37" lower_limit="1.99" upper_limit="2.82"/>
                    <measurement group_id="O9" value="2.2" lower_limit="1.86" upper_limit="2.6"/>
                    <measurement group_id="O10" value="2.36" lower_limit="1.98" upper_limit="2.8"/>
                    <measurement group_id="O11" value="2" lower_limit="1.69" upper_limit="2.37"/>
                    <measurement group_id="O12" value="2.24" lower_limit="1.91" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC 40mths N=32,36,17,33,0,20,22,26,26,24,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" lower_limit="3.85" upper_limit="11"/>
                    <measurement group_id="O2" value="7.02" lower_limit="4.33" upper_limit="11"/>
                    <measurement group_id="O3" value="23" lower_limit="11" upper_limit="46"/>
                    <measurement group_id="O4" value="4.29" lower_limit="2.59" upper_limit="7.11"/>
                    <measurement group_id="O5" value="NA">Zero participants analyzed</measurement>
                    <measurement group_id="O6" value="3.18" lower_limit="1.98" upper_limit="5.1"/>
                    <measurement group_id="O7" value="2.68" lower_limit="1.71" upper_limit="4.2"/>
                    <measurement group_id="O8" value="4.17" lower_limit="2.77" upper_limit="6.27"/>
                    <measurement group_id="O9" value="5.45" lower_limit="3.62" upper_limit="8.2"/>
                    <measurement group_id="O10" value="4.98" lower_limit="3.26" upper_limit="7.62"/>
                    <measurement group_id="O11" value="6.45" lower_limit="4.22" upper_limit="9.86"/>
                    <measurement group_id="O12" value="NA">Zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC 60mths N=32,34,17,31,42,21,24,22,21,22,24,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" lower_limit="3.28" upper_limit="7.55"/>
                    <measurement group_id="O2" value="4.69" lower_limit="3.13" upper_limit="7.04"/>
                    <measurement group_id="O3" value="14" lower_limit="8.15" upper_limit="26"/>
                    <measurement group_id="O4" value="6.77" lower_limit="4.43" upper_limit="10"/>
                    <measurement group_id="O5" value="3.93" lower_limit="2.73" upper_limit="5.65"/>
                    <measurement group_id="O6" value="2.75" lower_limit="1.77" upper_limit="4.26"/>
                    <measurement group_id="O7" value="2.86" lower_limit="1.9" upper_limit="4.3"/>
                    <measurement group_id="O8" value="3.22" lower_limit="2.11" upper_limit="4.92"/>
                    <measurement group_id="O9" value="4.02" lower_limit="2.6" upper_limit="6.21"/>
                    <measurement group_id="O10" value="4.85" lower_limit="3.17" upper_limit="7.4"/>
                    <measurement group_id="O11" value="6.27" lower_limit="4.18" upper_limit="9.41"/>
                    <measurement group_id="O12" value="9.46" lower_limit="6.48" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW 40mths N=33,37,17,34,0,28,23,27,28,25,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="13" upper_limit="42"/>
                    <measurement group_id="O2" value="27" lower_limit="15" upper_limit="47"/>
                    <measurement group_id="O3" value="22" lower_limit="9.65" upper_limit="50"/>
                    <measurement group_id="O4" value="26" lower_limit="14" upper_limit="46"/>
                    <measurement group_id="O5" value="NA">Zero participants analyzed</measurement>
                    <measurement group_id="O6" value="3.86" lower_limit="2.15" upper_limit="6.93"/>
                    <measurement group_id="O7" value="6.77" lower_limit="3.55" upper_limit="13"/>
                    <measurement group_id="O8" value="12" lower_limit="6.72" upper_limit="22"/>
                    <measurement group_id="O9" value="7.55" lower_limit="4.22" upper_limit="14"/>
                    <measurement group_id="O10" value="23" lower_limit="13" upper_limit="43"/>
                    <measurement group_id="O11" value="16" lower_limit="8.63" upper_limit="30"/>
                    <measurement group_id="O12" value="NA">Zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW 60mths N=32,34,18,31,42,26,25,23,24,21,24,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="10" upper_limit="32"/>
                    <measurement group_id="O2" value="35" lower_limit="20" upper_limit="60"/>
                    <measurement group_id="O3" value="34" lower_limit="16" upper_limit="72"/>
                    <measurement group_id="O4" value="26" lower_limit="15" upper_limit="45"/>
                    <measurement group_id="O5" value="6.51" lower_limit="3.99" upper_limit="11"/>
                    <measurement group_id="O6" value="3.77" lower_limit="2.14" upper_limit="6.64"/>
                    <measurement group_id="O7" value="7.26" lower_limit="4.08" upper_limit="13"/>
                    <measurement group_id="O8" value="10" lower_limit="5.77" upper_limit="19"/>
                    <measurement group_id="O9" value="7.02" lower_limit="3.9" upper_limit="13"/>
                    <measurement group_id="O10" value="24" lower_limit="13" upper_limit="45"/>
                    <measurement group_id="O11" value="19" lower_limit="11" upper_limit="35"/>
                    <measurement group_id="O12" value="5.02" lower_limit="2.88" upper_limit="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY 40mths N=33,37,17,34,0,28,23,27,28,25,24,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="13" upper_limit="38"/>
                    <measurement group_id="O2" value="15" lower_limit="9.16" upper_limit="26"/>
                    <measurement group_id="O3" value="27" lower_limit="13" upper_limit="58"/>
                    <measurement group_id="O4" value="9.33" lower_limit="5.48" upper_limit="16"/>
                    <measurement group_id="O5" value="NA">Zero participants analyzed</measurement>
                    <measurement group_id="O6" value="5.54" lower_limit="3.39" upper_limit="9.06"/>
                    <measurement group_id="O7" value="4.3" lower_limit="2.49" upper_limit="7.4"/>
                    <measurement group_id="O8" value="7.41" lower_limit="4.5" upper_limit="12"/>
                    <measurement group_id="O9" value="3.96" lower_limit="2.42" upper_limit="6.46"/>
                    <measurement group_id="O10" value="13" lower_limit="7.47" upper_limit="21"/>
                    <measurement group_id="O11" value="11" lower_limit="6.2" upper_limit="18"/>
                    <measurement group_id="O12" value="NA">Zero participants analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY 60mths N=33,34,17,31,42,28,25,23,23,21,23,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6.87" upper_limit="18"/>
                    <measurement group_id="O2" value="17" lower_limit="10" upper_limit="27"/>
                    <measurement group_id="O3" value="16" lower_limit="8.03" upper_limit="32"/>
                    <measurement group_id="O4" value="7.24" lower_limit="4.35" upper_limit="12"/>
                    <measurement group_id="O5" value="4.36" lower_limit="2.81" upper_limit="6.75"/>
                    <measurement group_id="O6" value="5.24" lower_limit="3.32" upper_limit="8.27"/>
                    <measurement group_id="O7" value="4.49" lower_limit="2.79" upper_limit="7.22"/>
                    <measurement group_id="O8" value="6.44" lower_limit="3.94" upper_limit="11"/>
                    <measurement group_id="O9" value="3.73" lower_limit="2.27" upper_limit="6.12"/>
                    <measurement group_id="O10" value="11" lower_limit="6.57" upper_limit="18"/>
                    <measurement group_id="O11" value="11" lower_limit="6.88" upper_limit="18"/>
                    <measurement group_id="O12" value="2.82" lower_limit="1.8" upper_limit="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 37 months overall (11 months of enrollment and 26 months of individual subject participation).</time_frame>
      <desc>The analyses for serious adverse events (SAEs) and adverse events (AEs) were done on the safety population (i.e., all subjects enrolled who received study vaccination and provided post-baseline safety data).</desc>
      <group_list>
        <group group_id="E1">
          <title>UK2,3,4,12+</title>
          <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 3, and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
        </group>
        <group group_id="E2">
          <title>UK2,4,12+</title>
          <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
        </group>
        <group group_id="E3">
          <title>UK2,4C/12+</title>
          <description>UK vaccine group receiving primary vaccine of monovalent MenC-CRM197 conjugate vaccine (Menjugate) at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
        </group>
        <group group_id="E4">
          <title>UK2,4,12-</title>
          <description>UK vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
        </group>
        <group group_id="E5">
          <title>UK Control</title>
          <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2, 3 and 4 months of age without any booster vaccination.</description>
        </group>
        <group group_id="E6">
          <title>Ca2,4,6+</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age without any booster vaccination.</description>
        </group>
        <group group_id="E7">
          <title>Ca2,4,6+/12PS</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2, 4 and 6 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age</description>
        </group>
        <group group_id="E8">
          <title>Ca2,4,12+</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a booster dose of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 12 months of age.</description>
        </group>
        <group group_id="E9">
          <title>Ca2,4+/12PS</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine with adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
        </group>
        <group group_id="E10">
          <title>Ca2,4,12-</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a booster vaccination of the quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 12 months of age.</description>
        </group>
        <group group_id="E11">
          <title>Ca2,4-/12PS</title>
          <description>Canadian vaccine group receiving primary vaccine of quadrivalent MenACWY-CRM197 conjugate vaccine without adjuvant at 2 and 4 months of age followed by a reduced booster vaccination of the quadrivalent MenACWY polysaccharide vaccine (Menomune [1/5 dose]) at 12 months of age.</description>
        </group>
        <group group_id="E12">
          <title>Ca Control</title>
          <description>Newly enrolled age-matched subjects that received a complete vaccination course of routine monovalent MenC conjugate vaccine at 2 and 12 months or only at 12 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Asperger's disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

